Non-Hodgkin Lymphoma
Conditions
Interventions
A:rhTPO 15000U injection everyday for 10 doses after chemotherapy
B:rhTPO 15000U injectioninjection at Day -4\-2\and day 2-9, total 10 doses.
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 to 70 years; 2. Histologically confirmed malignant tumor; 3. Will receive chemotherapy of high dose cytarabine (4g/m2/cycle) for at least 2 cycles; 4. ECOG PS score =2.0*10^9/L; (2) Hemoglobin >=90g/L; (3) Platelet count >=100*10^9/L; (4) Serum total bilirubin <=1.5*ULN (upper limit of normal); (5) Serum AST and ALT <2.5*ULN; (6) Serum creatinine <=1.5*ULN; (8) INR <=1.5; 6. Give signed informed consent before enrollment.
Exclusion criteria
Exclusion criteria: 1. Severe internal bleeding or intracranial hemorrhage; 2. Allergy to any agent of the study medicines; 3. Withdraw origin treatment because of severe side effects; 4. Function impairment of vital organs (heart, lung, kidney, etc), serious infection or >grade 2 adverse events; 5. Neurological or mental abnormalities that may affect cognitive assessment and inform consent; 6. Other psychological, family or social reason, which the researcher think would affect compliance with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of thrombocytopenia; | — |
Secondary
| Measure | Time frame |
|---|---|
| lasting time of thrombocytopenia;quantity of platelet transfusion;Safety profile; | — |
Countries
China
Contacts
Public ContactTongyu Lin
Outcome results
None listed